Long-term efficacy of Gilenya reinforced by new analysis

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Long-term efficacy of Gilenya reinforced by new analysis

Post by MSUK » Mon Oct 12, 2015 12:46 am

Novartis has announced a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya. The analysis evaluated the proportion of Gilenya patients with relapsing-remitting multiple sclerosis (RRMS) achieving 'no evidence of disease activity' (NEDA-4) every year over seven years... Read More - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/

Post Reply
  • Similar Topics
    Replies
    Views
    Last post